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Abstract
Background: This study aimed to investigate the relationships among osteocalcin, leptin and metabolic health
outcomes in children ages 9–13 years.
Methods: This was a cross-sectional analysis of baseline data from 161 boys and 157 girls (ages 9–13 years) who
previously participated in a double-blinded randomized placebo controlled trial of vitamin D supplementation.
Relationships among fasting serum total osteocalcin (tOC), undercarboxylated osteocalcin (ucOC), leptin, and
metabolic health outcomes were analyzed.
Results: Approximately 52% of study participants were obese based on percent body fat cutoffs (>25% for boys
and >32% for girls) and about 5% had fasting serum glucose within the prediabetic range (i.e. 100 to 125 mg/dL).
Serum tOC was not correlated with leptin, glucose, insulin, HOMA-IR, or HOMA-β after adjusting for percent body fat.
However, serum ucOC negatively correlated with leptin (partial r =−0.16; p = 0.04) and glucose (partial r = −0.16; p = 0.04)
after adjustment for percent body fat. Leptin was a positive predictor of insulin, glucose, HOMA-IR, and HOMA-β after
adjusting for age, sex and percent body fat (all p< 0.001).
Conclusions: These data depict an inverse relationship between leptin and various metabolic health outcomes in
children. However, the notion that tOC or ucOC link fat with energy metabolism in healthy children was not supported.
Clinical trial registration number: NCT00931580.
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Background
The relationships between bone, adiposity and energy
metabolism have been of recent interest [1–7]. Whereas
excess adiposity may benefit bone development as a result
of earlier and prolonged maturation [8], some studies have
identified fat mass as a negative determinant of skeletal
endpoints after adjusting for pertinent confounders [8, 9].
One explanation for a potentially adverse influence of
adiposity on bone involves obesity-related metabolic
health outcomes, specifically insulin resistance [10]. This
is of particular importance considering that obese children
are overrepresented in pediatric skeletal fracture cases
[11], and that certain bone-derived factors are understood
to contribute to energy metabolism [12]. Therefore, eluci-
dating the mechanisms by which adiposity influences
bone, as well as how bone-derived factors influence the
fat-bone relationship and metabolic health, warrants
further investigation.
Leptin is a hormone that has received considerable
attention in relation to the fat-bone connection, despite
its better-known role in appetite regulation [1]. Leptin
has been shown to influence bone through numerous
mechanisms [1], thus it is not surprising that the role of
leptin on bone is both complex and controversial [13].
Ducy et al. [1] identified leptin as a potent inhibitor of
bone formation acting through a central nervous system
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mechanism. In mice, intracerebroventricular leptin infu-
sion stimulated hypothalamic leptin receptor (LEPR) ex-
pression, promoting norepinephrine release, and in turn,
activating osteoblast β2-adrenergic receptors. Ultimately,
this resulted in altered bone metabolism in favor of bone
resorption [1, 14]. Conversely, peripheral leptin signaling
through LEPR in bone marrow stromal cells promoted
differentiation to the osteoblastic lineage over the adipo-
cytic lineage [15]. Further, LEPR signaling in osteoblasts
increased osteoprotegerin (OPG) and decreased the re-
ceptor activator of nuclear factor κB ligand (RANKL),
resulting in decreased osteoclastogenesis. Thus, in con-
trast to the bone-resorptive effects of leptin via the central
nervous system, peripheral leptin signaling at the level of
the skeleton appears to favor bone formation [13].
The bone-derived osteocalcin, a protein produced by
osteoblasts, is also suspected to play an integral role in
the link between fat, bone, and metabolic health [16, 17].
However, there is still considerable debate surrounding
the role of osteocalcin, including its sub-fractions (i.e.,
carboxylated [cOC] and undercarboxylated [ucOC]), in
the complex fat-bone connection. This is especially true
for pediatric populations. Osteocalcin-null mice versus
wild-type littermates have greater visceral fat, and
consequently, present with hyperglycemia and are
insulin resistant [3]. In humans, there is conflicting
evidence for a relationship between tOC and glucose
metabolism with some reports showing no relationship
[18, 19], and others showing an inverse relationship
between tOC and glucose concentrations [20–22]. In
contrast, ucOC seems to play a role in pancreatic β-
cell proliferation and insulin secretion, as well as
improving peripheral insulin sensitivity through the
regulation of the adipokine adiponectin [3, 4]. Whereas
experimental [3, 4] studies have suggested that ucOC
might play a more pivotal role in energy homeostasis
than tOC, obese versus normal weight children have
lower tOC, which is a negative predictor of serum lep-
tin and insulin resistance [23], thus the relative import-
ance of tOC and ucOC on metabolic health is not
currently well defined. Additionally, the effects of phys-
ical activity through skeletal loading on the bone-fat-
energy metabolism relationship have been described,
with ucOC proposed as an endocrine mediator com-
municating the energy needs of bone during physical
activity [7, 24, 25].
The objective of this study was to examine relation-
ships among serum osteocalcin (tOC and ucOC) and
leptin with metabolic health outcomes in a large cohort
of boys and girls who were at the early stages of matur-
ation. We hypothesized that leptin and osteocalcin
would be negatively related to one another, and that
leptin would be a negative predictor of serum glucose, in-
sulin and insulin resistance. In addition, we hypothesized
that ucOC would be a consistent positive predictor of the
various metabolic health outcomes.
Methods
Study design and population
This study is a cross sectional ancillary analysis of base-
line data from a previously conducted double blinded
placebo-controlled vitamin D supplementation trial [26]
which included 318 boys and girls ages 8 to 13 years living
in the United States (i.e., The GAPI Trial – University of
Georgia [UGA], Purdue University [PU] and Indiana
University [IU]). All study participants were healthy and
absent of any chronic diseases, as determined by self- and
parental report. Inclusion criteria included black and
white non-Hispanic girls and boys, and sexual maturity
stage 2 and 3, which was self-assessed as previously de-
scribed [26]. Exclusion criteria included menarche in girls,
growth disorders, or any disease, medication, or condition
known to influence bone metabolism. The GAPI study
was approved by the Institutional Review Boards for
Human Subjects at Purdue University, the University of
Georgia, and Indiana University School of Medicine. All
participants and their parents or legal guardians provided
informed assent and consent, respectively.
Study variables
Blood samples were collected after 12-h fasting for the
biochemical analyses of serum glucose, insulin, tOC,
ucOC and leptin. Serum was stored at −80 °C until ana-
lysis. Each analyte was measured at a single laboratory
for all participants.
Serum tOC and ucOC were measured in duplicate by
enzyme-linked immunosorbent assay (ELISA; tOC:
MicroVue™, Quidel Corp., San Diego, CA; ucOC: Takara
Bio, Inc., Japan). Intra- and interassay CVs for tOC were
4.8-9.8 and 4.8-10.0%, respectively; Mean intra- and
interassay CVs for ucOC were 5.2 and 8.3%, respectively.
Serum ucOC measurements were only available for 170
subjects. Serum leptin and insulin were measured in
duplicate by radioimmunoassay (RIA; EMD Milipore,
Billerica, MA). Mean intra- and interassay CVs for insu-
lin were 3.5 and 5.3%, respectively; and 5.0 and 4.5% for
leptin, respectively. Serum glucose was measured in trip-
licate by microtiter modification of the enzymatic Auto-
kit Glucose method (Wako Chemicals USA, Richmond,
VA). The mean intra- and interassay CVs were 1.8 and
2.2%, respectively. The Homeostasis Model of Assess-
ment Estimate of Insulin Resistance (HOMA-IR) was
calculated as: fasting glucose (mg/dL) x fasting insulin
(μU/mL)/405. The Homeostatic Model of Assessment
Estimate of β Cell Function (HOMA-β) was calcu-
lated as: [360 x fasting insulin (μU/mL)]/[fasting glu-
cose (mg/dL) – 63]. Height and weight were measured
and BMI-for-age percentiles were calculated from the
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2000 CDC Growth Charts [27], and obese status was de-
fined according to percent body fat cutoffs (>25 for boys
and >32% for girls) [9, 28, 29].
Percent body fat was assessed using dual-energy X-ray
absorptiometry (DXA; Delphi-A, Hologic Inc [UGA];
Lunar iDXA, GE Medical Instruments [PU]; and
Hologic Discovery-W [IU]). The same technician at
each site conducted scans and performed analyses
using instrument-specific software and protocols. De-
tailed procedures are described previously [26].
Statistical analysis
Descriptive statistics were used for characterization of
the study subjects. The normality of the distribution of
each variable was assessed using the Shapiro-Wilk test,
and variables were analyzed after logarithmic transform-
ation. Means for quantitative variables were compared
by Student’s t-tests or analysis of variance (ANOVA).
Pearson correlations, partial correlations and linear re-
gression analyses were used to determine relationships
among variables with adjustments for potential con-
founding variables. Percent body fat was included as a
covariate while examining the relationships between lep-
tin, osteocalcin, and metabolic health outcomes. Partial
correlations adjusted for percent body fat or BMI yielded
similar results. Sample size for individual analyses varied
according to data availability for each variable, and are
described in the tables. Statistical analyses were per-
formed using the Statistical Analysis Software, version
9.4 (Cary, NC). Statistical significance for all analyses
was set at α = 0.05.
Results
Anthropometrics and biochemistry
Descriptive participant characteristics are presented in
Table 1. The percentage of participants in sexual matur-
ation stages 2 and 3 were 65% and 35%, respectively.
Girls compared with boys were younger, shorter, and
had higher percent body fat, serum leptin, and HOMA-β
(all p < 0.001). Blacks compared with whites were youn-
ger, had higher BMI-for-age percentile, higher serum
leptin, higher HOMA-β and higher serum tOC, but
lower serum ucOC (all p < 0.050). Black females pre-
sented higher serum insulin concentrations and higher
HOMA-IR, when compared with all other race by sex
subgroups (both p < 0.050; Table 1).
Fifteen of the 318 total subjects (4.7%) had fasting
serum glucose concentrations within the pre-diabetic
range (≥100 < 125 mg/dL), with 110 mg/dL being the
highest observed value. Based on percent body fat cut-
offs [9, 28, 29], 51.8% (n = 156) of participants were clas-
sified as obese. Compared with the non-obese subjects,
obese individuals had higher serum leptin, insulin,
HOMA-IR and HOMA-β (all p < 0.0001), and lower
tOC (p = 0.0002) (Table 2). However, ucOC concentra-
tions did not differ between non-obese and obese
groups.
Table 1 Anthropometric and biochemical characterization of the population according to sex and race
Total Black male
(n = 82)
Black female
(n = 80)
White male
(n = 79)
White female
(n = 77)
Effects
Sex Race Sex x race
n Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) p-value p-value p-value
Age (years) 318 11.4 (0.1) 11.8 (0.1) 10.5 (0.1) 12.1 (0.1) 11.0 (0.1) <0.0001 0.0006 0.5396
Anthropometry
Weight (kg) 318 47.5 (0.7) 49.4 (1.4) 48.0 (1.3) 48.0 (1.5) 44.4 (1.1) 0.1181 0.0647 0.5113
Height (m) 318 1.51 (0.01) 1.52 (0.01) 1.48 (0.01) 1.54 (0.01) 1.49 (0.01) <0.0001 0.1555 0.7783
BMI-for-age (percentile) 318 68.3 (1.6) 72.1 (2.9) 77.6 (3.1) 56.9 (3.6) 66.5 (3.1) 0.1036 0.0013 0.3239
Body fat (%) 301 29.9 (0.6) 25.5 (1.0) 33.2 (0.9) 28.3 (1.1) 33.3 (1.0) <0.0001 0.1386 0.1832
Biochemistry
Leptin (ng/mL) 305 11.1 (0.6) 8.1 (0.9) 16.0 (1.2) 8.7 (1.2) 11.6 (0.9) <0.0001 0.0269 0.4041
ucOC (ng/mL) 170 30.6 (1.4) 20.3 (2.4) 27.6 (2.6) 39.8 (1.7) 41.8 (3.1) 0.1415 <0.0001 0.1805
Total osteocalcin (ng/mL) 303 33.3 (0.7) 38.5 (1.5) 35.5 (1.6) 29.8 (0.9) 29.5 (0.8) 0.1457 <0.0001 0.2302
Glucose (mg/dL) 317 89.0 (0.4) 89.4 (0.8) 89.4 (0.8) 89.1 (0.8) 87.9 (0.8) 0.4352 0.2441 0.4378
Insulin (μU/mL) 318 20.3 (0.6) 18.9 (0.8) 25.9 (1.5) 18.1 (1.4) 18.0 (0.9) 0.0006 <0.0001 0.0236
HOMA-β 317 307.3 (13.9) 301.5 (31.8) 389.4 (36.6) 263.4 (20.7) 274.2 (13.2) 0.0007 0.0015 0.1704
HOMA-IR 317 4.5 (0.1) 4.2 (0.2) 5.7 (0.3) 4.0 (0.3) 4.0 (0.2) 0.0020 <0.0001 0.0257
Standard Error of the Mean; Body mass index; Undercarboxylated osteocalcin; Homeaostasis Model of Assessment Estimate of β Cell Function; Homeaostasis
Model of Assessment Estimate of Insulin Resistance; Results of two-way ANOVA for sex, race and sex x race interactions investigated. All variables were analyzed
after logarithmic transformation
The values that are italic are p-values indicating significance
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Correlations with tOC and ucOC
In the unadjusted analyses, tOC was weakly negatively
correlated with leptin and weakly positively correlated
with height, but not correlated with any other anthropo-
metric or biochemical outcomes (Table 3). After adjust-
ing for percent body fat, tOC did not correlate with any
of our biochemical outcomes, height or weight. Only
after adjusting for percent body fat, ucOC was weakly
negatively correlated with leptin and glucose. As
depicted in Fig. 1, leptin remained positively, albeit
weakly, associated with ucOC after adjusting for age,
sex, and percent body fat.
Correlations with leptin
Leptin was strongly positively correlated with per-
cent body fat (r = 0.878, p < 0.0001) and modestly
positively correlated with BMI-for-age percentile (r = 0.596,
p < 0.0001). After adjusting for age, sex, and percent body
fat, leptin was a positive predictor of serum glucose (partial
r = 0.20, p = 0.001, β = 0.4229), serum insulin (partial r =
0.47, p < 0.0001, β = 0.9245), HOMA-β (partial r = 0.29,
p < 0.0001, β = 0.5805), and HOMA-IR (partial r = 0.48,
p < 0.0001, β = 0.9481), although the strength of these
associations were weak to moderate (Fig. 2).
Discussion
Recent findings have identified new potential metabolic
interactions between the skeleton, fat tissue, and energy
metabolism. Whereas insulin is involved in skeletal
development via the bone-forming osteoblasts [30],
Karsenty & Ferron [31] have suggested that insulin, bone
resorption, and osteocalcin activity are regulated by a
feed forward loop, in which insulin signaling in osteo-
blasts decreases the expression of the gene that encodes
the osteoprotegerin (Opg), thus increasing osteoclast-
mediated bone resorption which occurs at a pH of 4.5.
This acidic pH favors the decarboxylation of osteocalcin,
releasing ucOC into the systemic circulation. Thereafter,
ucOC plays a regulatory role in glucose metabolism by
promoting pancreatic insulin secretion [32] and periphe-
ral insulin sensitivity [3, 4, 12]. Furthermore, leptin has
been shown to modulate insulin sensitivity by reducing
osteocalcin bioactivity in osteoblasts [2]. Limited clinical
Table 2 Biochemical characterization of the population according to nutrition status defined by percent body fat cutoffs [9, 28, 29]
Non-obese (n = 145) Obese (n = 156) p-value
n Mean (SEM) Mean (SEM)
Leptin (ng/mL) 288 5.1 (0.3) 16.9 (0.8) <0.0001
ucOC (ng/mL) 167 30.6 (2.1) 30.8 (1.9) 0.8644
Total osteocalcin (ng/mL) 286 36.2 (1.1) 31.3 (0.8) 0.0002
Glucose (mg/dL) 300 88.8 (0.6) 89.5 (0.5) 0.3608
Insulin (μU/mL) 301 17.1 (0.6) 23.6 (1.0) <0.0001
HOMA-β 300 256.2 (10.8) 355.8 (25.7) <0.0001
HOMA-IR 300 3.8 (0.1) 5.2 (0.2) <0.0001
Standard Error of the Mean; Body mass index; Undercarboxylated osteocalcin; Homeostasis Model of Assessment Estimate of β Cell Function; Homeostasis Model
of Assessment Estimate of Insulin Resistance. Results of Student’s T-test. All variables were analyzed after logarithmic transformation
The values that are italic are p-values indicating significance
Table 3 Unadjusted correlation and partial correlation adjusted for percent body fat of total osteocalcin and undercarboxylated
osteocalcin with biochemical variables
Total osteocalcin Undercarboxylated osteocalcin
Unadjusted Adjusted for percent body fat Unadjusted Adjusted for percent body fat
n r p n r p n r p n r p
Leptin 303 –0.169 0.0031 286 0.041 0.4861 170 –0.037 0.6285 167 –0.162 0.0368
Insulin 303 0.001 0.9864 286 0.096 0.1057 170 –0.048 0.5345 167 –0.076 0.3282
Glucose 302 –0.026 0.6495 285 –0.033 0.5793 169 –0.150 0.0511 166 –0.159 0.0420
HOMA–IR 302 –0.006 0.9149 285 0.082 0.1666 169 –0.066 0.3965 166 –0.096 0.2185
HOMA–β 302 0.007 0.9060 285 0.096 0.1076 169 0.049 0.5229 166 0.036 0.6488
Weight 303 –0.008 0.8904 286 0.097 0.1028 170 –0.056 0.4672 167 –0.102 0.1923
Height 303 0.135 0.0183 286 0.101 0.0901 170 0.033 0.6641 167 0.035 0.6589
Homeostasis Model of Assessment Estimate of Insulin Resistance; Homeostasis Model of Assessment Estimate of β Cell Function; All variables were analyzed after
logarithmic transformation
The values that are italic are p-values indicating significance
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Fig. 1 Partial regression plots between ucOC and (a) glucose and (b) leptin adjusted for age, sex and percent body fat in children living in the
United States
Fig. 2 Partial regression plots between leptin and (a) serum insulin, (b) HOMA-IR, (c) HOMA-β, and (d) serum glucose adjusted for age, sex and
percent body fat among children living in the United States
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studies have investigated the relationships between
fat- and bone-derived hormonal mediators and energy
metabolism [12, 18, 24, 33], and data in youth are
sparse. Therefore, the primary aim of this study was
to examine the relationships between osteocalcin and
leptin with various metabolic health outcomes in a
large cohort of early adolescent boys and girls living
in the United States. Despite a weak negative correl-
ation between leptin and ucOC, we did not find a re-
lation between osteocalcin and insulin resistance or
other metabolic health outcomes. This finding corrob-
orates with the results from Abseyi et al. [18], in
which 150 obese non-diabetic children and adoles-
cents were evaluated and no relationship between
osteocalcin and insulin resistance was found, however
only tOC was assessed in that study. Another study
of 248 young Finnish women also found no correla-
tions among osteocalcin (tOC, cOC, or ucOC), glu-
cose, insulin, and HOMA-IR [19].
Corroborating the conclusions of various other studies,
data from the current study do not support the notion
that osteocalcin plays a role in glucose metabolism in our
cohort of children living in the United States. One key
characteristic of our study participants is that they were
recruited to be generally healthy and absent of any
chronic disease, including prediabetes or type 2 diabetes.
This is an important consideration given that the role of
osteocalcin in energy metabolism may be dependent upon
the presence of chronic disease. We found, however, an
obesity-related difference in tOC. Takaya et al. [33] ob-
served that adolescents with type 2 diabetes had lower
ucOC levels than normal weight controls, while no differ-
ence was found between non-diabetic obese subjects and
controls. In addition, differences in tOC were not observed.
Another study has shown that, in overweight children
only, tOC and cOC were significant negative predictors of
long-term glucose control (i.e., HbA1C) [34]. Further, it
is possible that osteocalcin may play a larger role in in-
dividuals with obesity-related chronic diseases such as
prediabetes or type 2 diabetes. Other studies consider-
ing individuals with obesity-related chronic diseases
showed similar results such that Rosato et al. [35] re-
ported that diabetic adults had 71% lower tOC concen-
trations than healthy controls. Improved glycemic
control after a 2-month intervention (therapy with in-
sulin or oral medication) among diabetic subjects was
associated with an increase in tOC concentrations. In
addition, change in tOC was a negative predictor of
fasting serum glucose concentrations in these same
study participants. Meanwhile, no significant correla-
tions were found between tOC and fasting glucose for
the healthy control group. Okazaki et al. [36] also
observed an increase in tOC after therapy in poorly
controlled noninsulin-dependent patients.
In addition to the relatively small number of studies
that have evaluated ucOC in relation to energy metab-
olism among adolescents, it is difficult to compare
across studies because the range of values for ucOC de-
pends on the assay employed. Applying the same
method of analysis used in our study (i.e., ELISA), Van
Summeren et al. [37] found mean ucOC concentrations
of 31.3 ng/mL among 86 children and adolescents from
3 to 18 years of age from the Netherlands. Rochefort et
al. [38] observed mean ucOC of 34.5 ng/mL among 13
nonobese children and 34.3 ng/mL among 27 obese chil-
dren aged 9 to 12 years old. Using RIA, Pollock et al. [12]
found mean ucOC of 5.6 ng/mL among normal glucose
subjects and 7.8 ng/mL among subjects with prediabetes
in a group of U.S. overweight children from 7 to 11 years
old. Tubic et al. [34], in a study with 108 Swedish 2–9 year
old children, found mean tOC and ucOC of 82.6 ng/mL
and 7.0 ng/mL, respectively, among normal weight sub-
jects and mean of 77.0 ng/mL and 7.9 ng/mL among
overweight subjects, however differences were not sig-
nificant. Alfadda et al. [39] found median levels of
0.53 ng/mL for cOC, 1.14 ng/mL for ucOC and 8.8 ng/
mL for tOC in a group of adults with type 2 diabetes,
and they were lower among overweight/obese adults in
comparison to what has been reported with normal in-
dividuals. In their study, however, tOC was unexpect-
edly higher than the value obtained by simply summing
the two individual fractions. While tOC was measured
by ELISA, Alfadda et al. [39] measured cOC and ucOC
fractions by enzyme immunoassay (EIA). For these rea-
sons, it is important to take note of the differences
among the methods established for measuring osteocal-
cin, considering that values derived from the RIA ap-
pear consistently lower than those from ELISA, the
latter of which we used in the current study.
In our study, leptin and ucOC were negatively corre-
lated independent of percent body fat. Leptin, in turn,
was a strong positive correlate of insulin resistance and
β-cell function. Despite the effect of leptin on reducing
insulin secretion [40], the positive correlation of leptin
with HOMA-β (an estimate of pancreatic β-cell function)
was expected. In non-diabetic populations – especially
among youth – increased insulin secretion precedes
insulin resistance [41] and, in the presence of obesity,
indicates a risk of developing type-2 diabetes [42]. In
contrast to earlier pediatric data, neither tOC nor
ucOC correlated with HOMA-β. Pollock et al. [12]
showed positive associations between ucOC and mul-
tiple markers of β-cell responsiveness. However, these
findings were evident only in children with pre-diabetes
and not those with normal glucose control. The par-
ticipants in the current study were healthy and absent
of any chronic diseases, thus the effect of osteocalcin
in modulating insulin secretion may be confined to
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individuals at risk of developing type-2 diabetes. These
data were later supported by Gower et al. [43], but ra-
ther in a cohort of overweight and obese adults (mean
age = 34.9 ± 8.3 years).
Sex-related differences in energy metabolism have been
well characterized, with girls being more insulin resistant
versus their male counterparts [44–46]. Sex steroids and
genetics may partially explain why girls are more inclined
than boys to develop disturbances in glucose metabolism
[46]. However, as shown by Jeffery et al. [47], the greater
adiposity in girls versus boys is also a contributor. In our
study, the higher percent body fat in girls was accom-
panied by higher HOMA-β with HOMA-IR being greatest
in black girls. Lee et al. [45] reported that female subjects
had significantly higher mean HOMA-IR than male sub-
jects (p = 0.02). In addition, overweight and obese adoles-
cents had higher HOMA-IR levels compared with normal
weight adolescents [45], and no other factor was more in-
fluential on HOMA-IR than obesity status. Consistent with
these findings, the overweight/obese versus normal weight
children in the current study had higher HOMA-IR values,
likely due to corresponding elevations in fasting serum in-
sulin in the overweight/obese individuals.
Racial differences in markers of insulin resistance and
sensitivity have been found by others [44, 48], but not
consistently in all studies [45]. We observed that black
subjects had higher HOMA-β, BMI-for-age percentile,
serum leptin and tOC than white subjects, and lower
ucOC. Black girls also had higher insulin, and conse-
quently HOMA-IR, than the other race by sex groups. A
meta-analysis with 74 study cohorts including 3,813 indi-
viduals showed that Africans had significantly lower insu-
lin sensitivity and higher insulin response than Caucasian
and East Asian subpopulations [48]. This study also found
that the stabilization points in the hyperbolic relationship
between insulin sensitivity and insulin response in Afri-
cans with normal glucose tolerance were located around
unstable extreme points in the curve, where a small
change in one variable is associated with a large nonlinear
change in the other variable. Therefore, among Africans,
even a small increase in insulin resistance could lead to a
rapid increase in the amount of released insulin required
to maintain normal glucose tolerance, which suggests that
this particular subpopulation is more vulnerable to the de-
velopment of type-2 diabetes. Indeed, the prevalence of
type-2 diabetes is 13.2% in people of African descent ver-
sus 7.6% in people of non-Hispanic European decent [49].
Our study has some limitations. Because of the cross-
sectional design, these results do not allow causal infer-
ence or temporal associations. Unfortunately, we were
unable to collect data on dynamic measures of periphe-
ral glucose metabolism or pancreatic β-cell function.
However, compared to an oral glucose tolerance test,
HOMA-IR performed well as a measure of glucose
metabolism in obese children and adolescents [50] and
has been used previously in pediatric populations of
similar age and stage of sexual maturation of the chil-
dren included in the present study [51]. Our study in-
cluded healthy children in a narrow range of puberty,
thus generalizability to children at all stages of matur-
ation is limited. Additionally, our subjects represented
otherwise healthy children and included only a small
number (i.e. < 5%) who presented with a fasting
serum glucose within the pre-diabetic range.
Conclusions
This ancillary cross-sectional analysis shows that leptin
concentrations negatively correlated with ucOC and
positively correlated with insulin resistance and β-cell
function estimates in healthy children. However, associa-
tions between OC and markers of energy metabolism were
not observed. Whereas our findings do not support the
position that OC plays a direct role in energy metabolism
in healthy children, these relationships warrant additional
attention within the context of obesity and/or obesity-
related chronic disease specifically through prospective
study designs throughout adolescence.
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